Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Return On Assets (ROA)?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Return On Assets (ROA) is 
0.02 (1Y -21.0% )

ALXN Stock Price & Return On Assets (ROA)

Return On Assets (ROA) for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Return On Assets (ROA)

chevron_right 2021 0.03 -0.9x *
( -7.2% / year avg)
chevron_left 1995 -0.22
vertical_align_top Peak 0.1 +1.43x *
vertical_align_bottom Bottom -0.22
arrow_drop_up # Up Years 14 14 of 27
years up.
arrow_drop_down # Down Years 13
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or -40.9x faster than it's return on assets (roa) over the same period.
  • If ALXN shrinks it's stock at the same rate as it's return on assets (roa) (-7.2%/year) , it's stock price will shrink +47.4% and hit $51.5 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 14 years (0%) it's return on assets (roa) were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
5-Year Change 🚀
+138%$6.4BNet Revenue (Sales)
+181%$608.8MCost of Revenue (Sales)
+135%$5.8BGross Profit Margin
-1.58%3.62Gross Profit Margin Ratio
+78.1%$1.2BResearch and Development (R&D)
+109%$1.8BSelling, General, and Administrative (SG&A)
+91.1%$3.2BTotal Operating Expenses
+101%$3.8BCost & Expenses
+38.7%$110.8MInterest Expense/Income, Net
+51.0%$300.4MDepreciation & Amortization (D&A)
+191%$2.9BEBITDA
+22.2%1.81EBITDA Margin
+227%$2.6BOperating Income
+37.0%1.63Operating Margin
-25.4%-$114.8MTotal Other Income/Expenses
+323%$2.4BPretax Income (Earnings)
+77.5%1.48Pretax Income (Earnings) Margin
-83.0%$219.2MProvision For Income Taxes
-391.6%$2.1BNet Income (Earnings)
-222.1%1.35Net Profit Margin
-401.9%9.78Earnings Per Share (EPS)
-401.9%9.78Earnings Per Share (EPS) Diluted
-3.15%$876.4MShares Outstanding
-3.15%$876.4MShares Outstanding (Diluted)
+154%$11.9BCash and Cash Equivalents
-88.2%$139.6MShort Term Investments
+105%$12.0BCash And Short-Term Investments
+227%$3.1BInventory
+135%$23.3BTotal Current Assets
+136%$5.8BPP&E
+1.69%$20.4BGoodwill
-37.3%$12.0BIntangible Assets
-17.4%$32.4BGoodwill and Intangible Assets
+37.6%$72.4BTotal Assets
+152%$474.4MAccounts Payables
-18.6%$569.6MShort-term Debt
+6,334%$1.1BOther Current Liabilities
+111%$6.5BTotal Current Liabilities
-27.2%$9.7BLong-term Debt
+291%$6.5BDeferred Tax Liabilities Non-Current
+147%$2.4BOther Non-Current Liabilities
+16.8%$19.3BTotal Non-Current Liabilities
+31.7%$25.8BTotal Liabilities
+370%$21.0BRetained Earnings
-331.5%-$500.0MAccumulated Other Comprehensive Income Loss
+41.2%$46.6BTotal Shareholders Equity
+37.6%$72.4BTotal Liabilities & Stockholders Equity
-26.8%$10.2BTotal Debt
-117.2%-$1.6BNet Debt
-128.0%-$436.8MDeferred Income Tax
+67.5%$342.0MStock-Based Compensation (SBC)
-1,029.8%$1.9BChange in Working Capital
+144%$176.4MAccounts Receivables
+145%$16.8BOther Working Capital
-154.3%-$67.2MOther Non-Cash Items
+276%$3.4BNet Cash Provided by Operating Activities
+1.9%-$310.0MInvestments in PP&E
-97.1%-$22.4MPurchase of Investments
-96.5%$10.0MSales/Maturities of Investments
-58.7%-$322.4MNet Cash used for Investing Activities
-16.7%-$306.0MCommon Stock Repurchased
-98.9%-$4.8MOther Financing Activities
-60.1%-$295.2MNet Cash Used Provided by Financing Activities
-1,272.3%$80.0MEffect of Exchange Rate Changes on Cash
-544.5%$2.8BNet Change in Cash
+160%$12.1BCash at End of Period
+76.1%$9.3BCash at Beginning of Period
+276%$3.4BOperating Cash Flow
+1.9%-$310.0MCapital Expenditure (capex)
+418%$3.1BFree Cash Flow
  • ALXN Historical Return On Assets (ROA) Table

    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Return On Assets (ROA) YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 0.03 134.9% - -
    4/1/2020 0.01 -63.5% - -
    4/1/2019 0.03 1248.4% - -
    4/1/2018 0.0 -72.8% - -
    4/1/2017 0.01 34.1% - -
    4/1/2016 0.01 -49.9% - -
    4/1/2015 0.01 -58.1% - -
    4/1/2014 0.03 6.0% - -
    4/1/2013 0.03 16.4% - -
    4/1/2012 0.03 -15.9% - -
    4/1/2011 0.03 -66.1% - -
    4/1/2010 0.1 156.9% - -
    4/1/2009 0.04 4187.0% - -
    4/1/2008 0.0 -100.9% - -
    4/1/2007 -0.09 -25.4% - -
    4/1/2006 -0.13 21.7% - -
    4/1/2005 -0.1 60.8% - -
    4/1/2004 -0.06 -11.3% - -
    4/1/2003 -0.07 48.1% - -
    4/1/2002 -0.05 201.2% - -
    4/1/2001 -0.02 -85.3% - -
    4/1/2000 -0.11 98.0% - -
    4/1/1999 -0.06 -31.3% - -
    4/1/1998 -0.08 170.8% - -
    4/1/1997 -0.03 -62.6% - -
    4/1/1996 -0.08 -63.4% - -
    4/1/1995 -0.22 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
  • Return on Assets = Net Income ÷ Average Total Assets
    In financial analysis, it is the measure of the return on investment. ROA is used in evaluating management's efficiency in using assets to generate income.

    For more detailed definitions, please see Investopedia.
    Year Return On Assets (ROA) YoY % Change Stock Price YoY % Change (Stock Price) net income total assets
    4/1/2021 0.03 134.9% 2143.20 72412.00
    4/1/2020 0.01 -63.5% 956.60 69944.70
    4/1/2019 0.03 1248.4% 1974.70 57314.20
    4/1/2018 0.00 -72.8% 152.90 54747.50
    4/1/2017 0.01 34.1% 507.34 53860.46
    4/1/2016 0.01 -49.9% 364.95 51953.36
    4/1/2015 0.01 -58.1% 231.11 34937.62
    4/1/2014 0.03 6.0% 484.59 14142.06
    4/1/2013 0.03 16.4% 352.86 11164.47
    4/1/2012 0.03 -15.9% 222.02 8375.43
    4/1/2011 0.03 -66.1% 153.59 4651.18
    4/1/2010 0.10 156.9% 307.71 3454.01
    4/1/2009 0.04 4187.0% 75.14 2036.18
    4/1/2008 0.00 -100.9% 5.48 1507.88
    4/1/2007 -0.09 -25.4% -119.21 1259.27
    4/1/2006 -0.13 21.7% -115.15 926.51
    4/1/2005 -0.10 60.8% -124.64 1235.21
    4/1/2004 -0.06 -11.3% -73.07 1142.37
    4/1/2003 -0.07 48.1% -83.04 1140.28
    4/1/2002 -0.05 201.2% -70.39 1437.45
    4/1/2001 -0.02 -85.3% -26.42 1615.21
    4/1/2000 -0.11 98.0% -44.60 675.95
    4/1/1999 -0.06 -31.3% -8.00 163.80
    4/1/1998 -0.08 170.8% -13.20 163.90
    4/1/1997 -0.03 -62.6% -4.10 96.00
    4/1/1996 -0.08 -63.4% -6.27 77.60
    4/1/1995 -0.22 -5.20 23.60